Scarica l'app Stockscreener
9.21
14.17%
-1.52
Dopo l'orario di chiusura:
9.39
0.18
+1.95%
Precedente Chiudi:
$10.73
Aprire:
$10.65
Volume 24 ore:
664.56K
Relative Volume:
1.59
Capitalizzazione di mercato:
$498.86M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-2.0553
EPS:
-4.481
Flusso di cassa netto:
-
1 W Prestazione:
-15.97%
1M Prestazione:
-5.34%
6M Prestazione:
-34.31%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.17
$10.68
Intervallo di 1 settimana:
$9.17
$11.47
Portata 52W:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Nome
Eikon Therapeutics Inc
Settore
Industria
Telefono
341-777-0566
Indirizzo
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
9.21 | 581.19M | 0 | 0 | 0 | -4.481 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Iniziato | BofA Securities | Buy |
| 2026-03-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Iniziato | JP Morgan | Overweight |
| 2026-03-02 | Iniziato | Mizuho | Outperform |
| 2026-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2026-02-26 | Iniziato | Wedbush | Underperform |
Mostra tutto
Eikon Therapeutics Inc Borsa (EIKN) Ultime notizie
Eikon Therapeutics at Cantor conference: selective cancer drugs advance By Investing.com - Investing.com India
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha
Eikon Therapeutics (NASDAQ:EIKN) Trading Up 6.9% After Insider Buying Activity - MarketBeat
Eikon Therapeutics (NASDAQ:EIKN) Raised to Strong-Buy at Mizuho - MarketBeat
Group Iv Gp Lp Column Buys 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock - MarketBeat
Open-market insider buy at Eikon Therapeutics (EIKN) - Stock Titan
Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com - Investing.com South Africa
Eikon Therapeutics Appoints CP Chang as Executive Vice President and Chief Scientific Officer - Quiver Quantitative
A Bristol Myers Squibb research leader joins Eikon as science chief - Stock Titan
BlackRock Inc. Buys 962,046 Shares of Eikon Therapeutics, Inc. $EIKN - MarketBeat
EDGAR Filing Documents for 0001193125-26-349936 - sec.gov
Eikon Therapeutics to Participate in Investor Conferences in September 2026 - The Manila Times
Eikon (EIKN) Financial Update: EPS Misses Its Estimate on the Day; After Results: The Stock Ends Up 12.46% in the Latest SessionProfit Announcement - vinanet.vn
Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com
Eikon Therapeutics adds Merck chemistry head to advisory board By Investing.com - Investing.com Nigeria
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald - Sahm
An oncology expert will discuss PARP drugs in four cancers Aug. 20 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
EIKN Q1 2026 Earnings: Deeper-than-Expected Loss but Shares Rally 6.97%Energy Earnings Report - vinanet.vn
$Eikon Therapeutics (EIKN.US)$ - Moomoo
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Australia
Eikon Therapeutics Updates Corporate Presentation, Files Form 8-K Under Regulation FD - kalkinemedia.com
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside - TradingView
Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k - simplywall.st
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee - marketscreener.com
Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary - TradingView
Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash - Stock Titan
Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - Yahoo Finance
FMR LLC Expands Eikon Therapeutics Inc (EIKN) Stake Despite Post-IPO Slide - GuruFocus
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma - The Manila Times
Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced Melanoma - marketscreener.com
EIKN Q1 2026 Earnings: Clinical-Stage Biotech's Loss Widens 38.3% Beyond Estimates; Shares Gain 5.14%Guidance Update - vinanet.vn
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. To Its Scientific Advisory Board - TradingView
Eikon Therapeutics adds Merck chemistry head to advisory board - Investing.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board - The Manila Times
Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board - Moomoo
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G - Stock Titan
Certain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.com
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock Titan
Eikon Therapeutics (EIKN) Holds Near $9.15 as Shares Consolidate Above Key SupportStock Analysis - vinanet.vn
S.F. heart drug developer Braveheart Bio poised for 2nd-largest biotech IPO this year - The Business Journals
Eikon Therapeutics : Company Presentation - marketscreener.com
Eikon Therapeutics, Inc.'s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th - MarketBeat
Eikon Therapeutics Shares Up on First Dose to Patient in Phase 2/3 Lung Cancer Trial - Moomoo
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Eikon Therapeutics doses first patient in lung cancer trial - Investing.com
Eikon Therapeutics Inc Azioni (EIKN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):